In the fast-paced world of early-phase drug development, successful formulation development is often the bridge between a promising molecule and a viable clinical candidate.
During BIO 2026 in San Diego, Henny Zijlstra, Chief Commercial Officer at Ardena, sat down with BioPharma Boardroom to discuss how integrated CDMO strategies are shaping the future of early-phase pipelines.
Building upon our previous discussions regarding bridging early development gaps, this conversation dives deeper into the specific therapeutic drivers, the pragmatic application of digitalization, and smart navigation under funding pressures.
Therapeutic Drivers: Where Complexity Meets Demand
Demand for specialized development services is particularly strong where standard platforms fall short. Oncology remains a dominant force, characterized by potent compounds, difficult solubility profiles, and intense pressure to reach clinical proof of concept efficiently. Similarly, rare disease programs demand extreme precision and accelerated pathways due to small patient populations.
Beyond these traditional strongholds, there is growing activity around advanced and precision medicine approaches, including oligonucleotides, peptides, complex injectables, and nanomedicine-based therapies. Successfully advancing these assets depends on specialist formulation expertise and deep cross-functional capabilities, from solid-state chemistry characterization to nanomedicine and lipid-based drug delivery systems.
Leveraging Data and AI in Formulation Development
While artificial intelligence and data analytics dominate industry headlines, their implementation in regulated environments requires careful calibration. Digital tools are most powerful when utilized as practical instruments to accelerate formulation development.
By leveraging structured data workflows, teams can better analyze patterns in solubility behaviour, stability trends, and process robustness across experiments. However, in the context of CMC and regulatory compliance, AI must support human scientific judgment rather than replace it. The ultimate goal of digitalization is to reduce blind alleys, streamline knowledge capture across sites, and drive faster, more confident technical decisions without compromising quality.
Overcoming Funding Pressures with Stage-Appropriate Scope
Financing constraints fundamentally change how biotech companies approach early-phase programs. Capital efficiency is paramount, meaning developers cannot afford unnecessary work or rigid development plans that do not serve the immediate value inflection point, whether that is a Series B financing round, a Phase 1 readout, or a partnering discussion.
A tailored approach to formulation development means knowing when to scale up and when to hold back. For instance, not every program requires an exhaustive ICH stability package or a definitive commercial formulation prior to entering the clinic. Experienced development partners add value by helping clients look around corners, identifying potential analytical gaps, manufacturing scalability issues, or drug absorption bottlenecks before they evolve into costly clinical delays or regulatory roadblocks. Flexibility in adapting scope and pace ensures that biotechs remain agile as new in vivo data emerges.
Strategic Priorities Moving Forward
The overarching trends at BIO 2026, ranging from complex molecules and rare disease urgency to capital constraints, underscore a clear market shift. Biotechs need development partners who bring proven scientific judgment to hard-to-formulate assets, including complex solid-state chemistry, nanomedicines, HPAPIs, sterile dosage forms, and targeted therapies. Bridging the gap between promising science and clinical reality requires foresight, integrated execution, and the ability to prevent costly missteps before they occur.
– This article is adapted from an exclusive interview originally published on BioPharma Boardroom.
